188 related articles for article (PubMed ID: 23098406)
1. [How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin].
Drapkina OM; Korneeva ON
Kardiologiia; 2012; 52(8):89-92. PubMed ID: 23098406
[No Abstract] [Full Text] [Related]
2. The Post-JUPITER trial era and the cost of preventive medicine.
Papadopoulos VP
Hellenic J Cardiol; 2010; 51(2):187-8. PubMed ID: 20378525
[No Abstract] [Full Text] [Related]
3. [Lipid lowering by rosuvastatin: how do statins differ?].
Laufs U
Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
[No Abstract] [Full Text] [Related]
4. Is Jupiter also a god of primary prevention?
Accad M; Fred HL
Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
[No Abstract] [Full Text] [Related]
5. Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?
Dubé MP
J Infect Dis; 2014 Apr; 209(8):1149-50. PubMed ID: 24415787
[No Abstract] [Full Text] [Related]
6. [Rosuvastatin has no effect on clinical outcomes in patients with heart failure. Results of the GISSI-HF trial].
Preorazhenskiĭ DV
Kardiologiia; 2009; 49(4):64-5. PubMed ID: 19463122
[No Abstract] [Full Text] [Related]
7. Rosuvastatin in patients with elevated C-reactive protein.
Davis CE
N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271278
[No Abstract] [Full Text] [Related]
8. Rosuvastatin in patients undergoing hemodialysis.
Kassimatis TI; Konstantinopoulos PA
N Engl J Med; 2009 Jul; 361(1):93; author reply 94-5. PubMed ID: 19579277
[No Abstract] [Full Text] [Related]
9. Rosuvastatin in patients undergoing hemodialysis.
de Oliveira JM
N Engl J Med; 2009 Jul; 361(1):93-4; author reply 94-5. PubMed ID: 19579278
[No Abstract] [Full Text] [Related]
10. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
[No Abstract] [Full Text] [Related]
11. Is chronic severe anemia an independent predictor of poor outcomes?
Anand IS
Cardiology; 2011; 120(2):89-90. PubMed ID: 22142636
[No Abstract] [Full Text] [Related]
12. [Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)].
Mareev VIu
Kardiologiia; 2008; 48(1):74-5. PubMed ID: 18261000
[No Abstract] [Full Text] [Related]
13. Rosuvastatin in patients with elevated C-reactive protein.
Jenny-Avital ER
N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
[No Abstract] [Full Text] [Related]
14. FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
Mitka M
JAMA; 2010 Apr; 303(13):1242-3. PubMed ID: 20371776
[No Abstract] [Full Text] [Related]
15. Rosuvastatin in patients with elevated C-reactive protein.
Koller MT; Bucher HC; Steyerberg EW
N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
[No Abstract] [Full Text] [Related]
16. Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Prescrire Int; 2011 Apr; 20(115):94. PubMed ID: 21648210
[No Abstract] [Full Text] [Related]
17. Regulatory divergence.
Breckenridge A
Clin Trials; 2011 Aug; 8(4):425-6; discussion 430-1. PubMed ID: 21835859
[No Abstract] [Full Text] [Related]
18. The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER.
Chapman MJ; Giral P; Barter PJ
Eur Heart J; 2013 May; 34(18):1318-20. PubMed ID: 23482520
[No Abstract] [Full Text] [Related]
19. Rosuvastatin in patients with elevated C-reactive protein.
Chan PS; Nallamothu BK; Hayward RA
N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
[No Abstract] [Full Text] [Related]
20. Balancing the cardiometabolic benefits and risks of statins.
Watts GF; Ooi EM
Lancet; 2012 Aug; 380(9841):541-3. PubMed ID: 22883491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
